- Lenorplastics Zug AG signs up as sales partner for Evonik PLEXIGLAS® molding compounds in Switzerland
Darmstadt, Germany. Effective immediately, Lenorplastics Zug AG will be marketing Evonik Industries’ entire portfolio of PLEXIGLAS® and PLEXIMID® molding compounds in Switzerland. A private enterprise, this Swiss company has been successfully engaged in the plastics market for more than 30 years, offering its customers high-end polymer products and expert technical service.
The extensive product range of PLEXIGLAS® molding compounds for injection molding and extrusion applications now ideally complements Lenorplastics Zug AG’s existing offerings.
Evonik’s PMMA specialty products are the perfect solution for applications requiring exceptional brilliance and transparency, unparalleled weather resistance, and excellent surface characteristics. The main uses for these products are in medical technology, in the automotive, watch-making, and lighting industries, in optics, communication, building, and household applications.
Cooperation between these two companies sees their respective strengths—marketing know-how and market expertise on the part of Lenorplastics Zug AG and quality PLEXIGLAS® molding compounds supplied by Evonik—ideally paired to create a formidable team campaign.
Evonik Industries is a worldwide manufacturer of PMMA products sold under the PLEXIGLAS® trademark on the European, Asian, African and Australian continents and under the ACRYLITE® trademark in the Americas.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.